Laura E Targownik

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4486507/publications.pdf

Version: 2024-02-01

220 papers

7,965 citations

50170 46 h-index 54797

g-index

225 all docs 225 docs citations

times ranked

225

8574 citing authors

#	Article	IF	CITATIONS
1	Risk of Developing Colorectal Cancer Following a Negative Colonoscopy Examination. JAMA - Journal of the American Medical Association, 2006, 295, 2366.	3.8	375
2	The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy. Gastroenterology, 2016, 150, 734-757.e1.	0.6	373
3	Use of proton pump inhibitors and risk of osteoporosis-related fractures. Cmaj, 2008, 179, 319-326.	0.9	352
4	Clinical Practice Guidelines for the Medical Management of Nonhospitalized Ulcerative Colitis: The Toronto Consensus. Gastroenterology, 2015, 148, 1035-1058.e3.	0.6	323
5	Past and Future Burden of Inflammatory Bowel Diseases Based on Modeling of Population-Based Data. Gastroenterology, 2019, 156, 1345-1353.e4.	0.6	273
6	Trends in Epidemiology of Pediatric Inflammatory Bowel Disease in Canada: Distributed Network Analysis of Multiple Population-Based Provincial Health Administrative Databases. American Journal of Gastroenterology, 2017, 112, 1120-1134.	0.2	241
7	The Epidemiology of Colectomy in Ulcerative Colitis: Results From a Population-Based Cohort. American Journal of Gastroenterology, 2012, 107, 1228-1235.	0.2	232
8	Proton-Pump Inhibitor Use Is Not Associated With Osteoporosis or Accelerated Bone Mineral Density Loss. Gastroenterology, 2010, 138, 896-904.	0.6	227
9	A Multicenter Observational Study of Incretin-based Drugs and Heart Failure. New England Journal of Medicine, 2016, 374, 1145-1154.	13.9	191
10	Colonic stent vs. emergency surgery for management of acute left-sided malignant colonic obstruction: a decision analysis. Gastrointestinal Endoscopy, 2004, 60, 865-874.	0.5	155
11	Proton pump inhibitors and the risk of hospitalisation for community-acquired pneumonia: replicated cohort studies with meta-analysis. Gut, 2014, 63, 552-558.	6.1	154
12	Introduction of anti-TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases: a population-based interrupted time series study. Gut, 2020, 69, 274-282.	6.1	145
13	Trends in Management and Outcomes of Acute Nonvariceal Upper Gastrointestinal Bleeding: 1993–2003. Clinical Gastroenterology and Hepatology, 2006, 4, 1459-1466.e1.	2.4	142
14	Surgical Rates for Crohnâ∈™s Disease are Decreasing: A Population-Based Time Trend Analysis and Validation Study. American Journal of Gastroenterology, 2017, 112, 1840-1848.	0.2	140
15	Endoscopic screening for esophageal varices in cirrhosis: Is it ever cost effective?. Hepatology, 2003, 37, 366-377.	3.6	137
16	Ranking microbiome variance in inflammatory bowel disease: a large longitudinal intercontinental study. Gut, 2021, 70, 499-510.	6.1	127
17	A comparison of the gut microbiome between long-term users and non-users of proton pump inhibitors. Alimentary Pharmacology and Therapeutics, 2016, 43, 974-984.	1.9	126
18	The Relationship Among Perceived Stress, Symptoms, and Inflammation in Persons With Inflammatory Bowel Disease. American Journal of Gastroenterology, 2015, 110, 1001-1012.	0.2	123

#	Article	IF	CITATIONS
19	The effect of proton pump inhibitors on fracture risk: report from the Canadian Multicenter Osteoporosis Study. Osteoporosis International, 2013, 24, 1161-1168.	1.3	120
20	The Relationship Between Proton Pump Inhibitor Use and Longitudinal Change in Bone Mineral Density: A Population-Based From the Canadian Multicentre Osteoporosis Study (CaMos). American Journal of Gastroenterology, 2012, 107, 1361-1369.	0.2	110
21	The Relative Efficacies of Gastroprotective Strategies in Chronic Users of Nonsteroidal Anti-inflammatory Drugs. Gastroenterology, 2008, 134, 937-944.e1.	0.6	109
22	Higher Incidence of Clostridium difficile Infection Among Individuals With Inflammatory Bowel Disease. Gastroenterology, 2017, 153, 430-438.e2.	0.6	109
23	The Prevalence and Predictors of Opioid Use in Inflammatory Bowel Disease: A Population-Based Analysis. American Journal of Gastroenterology, 2014, 109, 1613-1620.	0.2	106
24	The Cost-Effectiveness of Cyclooxygenase-2 Selective Inhibitors in the Management of Chronic Arthritis. Annals of Internal Medicine, 2003, 138, 795.	2.0	105
25	Selective Serotonin Reuptake Inhibitors Are Associated With a Modest Increase in the Risk of Upper Gastrointestinal Bleeding. American Journal of Gastroenterology, 2009, 104, 1475-1482.	0.2	99
26	Infectious and Malignant Complications of TNF Inhibitor Therapy in IBD. American Journal of Gastroenterology, 2013, 108, 1835-1842.	0.2	97
27	Rural and Urban Residence During Early Life is Associated with Risk of Inflammatory Bowel Disease: A Population-Based Inception and Birth Cohort Study. American Journal of Gastroenterology, 2017, 112, 1412-1422.	0.2	88
28	Association Between Incretin-Based Drugs and the Risk of Acute Pancreatitis. JAMA Internal Medicine, 2016, 176, 1464.	2.6	87
29	AGA Clinical Practice Update on De-Prescribing of Proton Pump Inhibitors: Expert Review. Gastroenterology, 2022, 162, 1334-1342.	0.6	86
30	Differences in the management of Crohn's disease among experts and community providers, based on a national survey of sample case vignettes. Alimentary Pharmacology and Therapeutics, 2007, 26, 1005-1018.	1.9	79
31	What Are Adults With Inflammatory Bowel Disease (IBD) Eating? A Closer Look at the Dietary Habits of a Populationâ€Based Canadian IBD Cohort. Journal of Parenteral and Enteral Nutrition, 2016, 40, 405-411.	1.3	79
32	The Prevalence of and the Clinical and Demographic Characteristics Associated With High-Intensity Proton Pump Inhibitor Use. American Journal of Gastroenterology, 2007, 102, 942-950.	0.2	78
33	Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study. BMJ, The, 2016, 352, i581.	3.0	78
34	The quality of published health economic analyses in digestive diseases: A systematic review and quantitative appraisal. Gastroenterology, 2004, 127, 403-411.	0.6	76
35	Clinical Practice Guideline for the Medical Management of Perianal Fistulizing Crohn's Disease: The Toronto Consensus. Inflammatory Bowel Diseases, 2019, 25, 1-13.	0.9	73
36	Predictors and risks for death in a population-based study of persons with IBD in Manitoba. Gut, 2015, 64, 1403-1411.	6.1	65

#	Article	IF	CITATIONS
37	The Impact of Inflammatory Bowel Disease in Canada 2018: Direct Costs and Health Services Utilization. Journal of the Canadian Association of Gastroenterology, 2019, 2, S17-S33.	0.1	63
38	The Role of Rapid Endoscopy for High-Risk Patients with Acute Nonvariceal Upper Gastrointestinal Bleeding. Canadian Journal of Gastroenterology & Hepatology, 2007, 21, 425-429.	1.8	62
39	Predicting complicated Crohn's disease and surgery: phenotypes, genetics, serology and psychological characteristics of a population-based cohort. Alimentary Pharmacology and Therapeutics, 2013, 38, 274-283.	1.9	62
40	Long-Term Proton Pump Inhibitor Use Is Not Associated With Changes in Bone Strength and Structure. American Journal of Gastroenterology, 2017, 112, 95-101.	0.2	62
41	Evidence of Bidirectional Associations Between Perceived Stress and Symptom Activity. Inflammatory Bowel Diseases, 2017, 23, 473-483.	0.9	57
42	Understanding and Avoiding Immortal-Time Bias in Gastrointestinal Observational Research. American Journal of Gastroenterology, 2015, 110, 1647-1650.	0.2	56
43	Events Within the First Year of Life, but Not the Neonatal Period, Affect Risk for Later Development of Inflammatory Bowel Diseases. Gastroenterology, 2019, 156, 2190-2197.e10.	0.6	53
44	Risk of Low Bone Mineral Density Associated With Psychotropic Medications and Mental Disorders in Postmenopausal Women. Journal of Clinical Psychopharmacology, 2011, 31, 56-60.	0.7	51
45	Risk factors and management of osteoporosis in inflammatory bowel disease. Current Opinion in Gastroenterology, 2014, 30, 168-174.	1.0	50
46	Performance of administrative case definitions for depression and anxiety in inflammatory bowel disease. Journal of Psychosomatic Research, 2016, 89, 107-113.	1.2	50
47	Prevalence of and Outcomes Associated with Corticosteroid Prescription in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2014, 20, 622-630.	0.9	49
48	Rural and urban disparities in the care of Canadian patients with inflammatory bowel disease: a population-based study. Clinical Epidemiology, 2018, Volume 10, 1613-1626.	1.5	48
49	Inflammatory bowel disease and the risk of osteoporosis and fracture. Maturitas, 2013, 76, 315-319.	1.0	46
50	The Impact of Inflammatory Bowel Disease in Canada 2018: A Scientific Report from the Canadian Gastro-Intestinal Epidemiology Consortium to Crohn's and Colitis Canada. Journal of the Canadian Association of Gastroenterology, 2019, 2, S1-S5.	0.1	46
51	Inflammatory Bowel Disease Has a Small Effect on Bone Mineral Density and Risk for Osteoporosis. Clinical Gastroenterology and Hepatology, 2013, 11, 278-285.	2.4	45
52	Characterization of Inflammatory Bowel Disease in Elderly Patients: A Review of Epidemiology, Current Practices and Outcomes of Current Management Strategies. Canadian Journal of Gastroenterology and Hepatology, 2015, 29, 327-333.	0.8	44
53	Low Prevalence of Disability Among Patients With Inflammatory Bowel Diseases a Decade After Diagnosis. Clinical Gastroenterology and Hepatology, 2014, 12, 1330-1337.e2.	2.4	40
54	The Cost-Effectiveness of Colonic Stenting as a Bridge to Curative Surgery in Patients with Acute Left-Sided Malignant Colonic Obstruction: A Canadian Perspective. Canadian Journal of Gastroenterology & Hepatology, 2006, 20, 779-785.	1.8	39

#	Article	IF	Citations
55	Predictors of Emergency Department Use by Persons with Inflammatory Bowel Diseases. Inflammatory Bowel Diseases, 2016, 22, 2907-2916.	0.9	39
56	Discontinuing Long-Term PPI Therapy: Why, With Whom, and How?. American Journal of Gastroenterology, 2018, 113, 519-528.	0.2	39
57	Longitudinal Trends in the Direct Costs and Health Care Utilization Ascribable to Inflammatory Bowel Disease in the Biologic Era: Results From a Canadian Population–Based Analysis. American Journal of Gastroenterology, 2020, 115, 128-137.	0.2	39
58	Gastrointestinal symptoms before and during menses in healthy women. BMC Women's Health, 2014, 14, 14.	0.8	38
59	Combined Biologic and Immunomodulatory Therapy is Superior to Monotherapy for Decreasing the Risk of Inflammatory Bowel Disease-Related Complications. Journal of Crohn's and Colitis, 2020, 14, 1354-1363.	0.6	38
60	Gastrointestinal symptoms before and during menses in women with <scp>IBD</scp> . Alimentary Pharmacology and Therapeutics, 2012, 36, 135-144.	1.9	36
61	Cesarean Section Delivery Is Not a Risk Factor for Development of Inflammatory Bowel Disease: A Population-based Analysis. Clinical Gastroenterology and Hepatology, 2016, 14, 50-57.	2.4	36
62	The Cost-Effectiveness of Hepatic Venous Pressure Gradient Monitoring in the Prevention of Recurrent Variceal Hemorrhage. American Journal of Gastroenterology, 2004, 99, 1306-1315.	0.2	35
63	Proton pump inhibitors, osteoporosis, and osteoporosis-related fractures. Maturitas, 2009, 64, 9-13.	1.0	35
64	Factors Associated with Discontinuation of Anti-TNF Inhibitors Among Persons with IBD. Inflammatory Bowel Diseases, 2017, 23, 409-420.	0.9	34
65	Temporal Trends in Initiation of Therapy With Tumor Necrosis Factor Antagonists for Patients With Inflammatory Bowel Disease: A Population-based Analysis. Clinical Gastroenterology and Hepatology, 2017, 15, 1061-1070.e1.	2.4	32
66	Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn's Disease. Clinical Gastroenterology and Hepatology, 2019, 17, 1680-1713.	2.4	32
67	Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn's Disease. Journal of the Canadian Association of Gastroenterology, 2019, 2, e1-e34.	0.1	32
68	The Effect of Initiation of Anti-TNF Therapy on the Subsequent Direct Health Care Costs of Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2019, 25, 1718-1728.	0.9	31
69	Pre-endoscopic proton pump inhibitor therapy reduces recurrent adverse gastrointestinal outcomes in patients with acute non-variceal upper gastrointestinal bleeding. Alimentary Pharmacology and Therapeutics, 2006, 24, 1247-1255.	1.9	29
70	Academic Performance among Children with Inflammatory Bowel Disease: A Population-Based Study. Journal of Pediatrics, 2015, 166, 1128-1133.	0.9	29
71	The Clinician's Guide to Proton Pump Inhibitor Related Adverse Events. Drugs, 2019, 79, 715-731.	4.9	29
72	The Impact of Inflammatory Bowel Disease in Canada 2018: IBD in Seniors. Journal of the Canadian Association of Gastroenterology, 2019, 2, S68-S72.	0.1	29

#	Article	IF	CITATIONS
73	Inflammatory bowel disease and new-onset psychiatric disorders in pregnancy and post partum: a population-based cohort study. Gut, 2019, 68, 1597-1605.	6.1	29
74	Inflammatory bowel disease and the risk of fracture after controlling for FRAX. Journal of Bone and Mineral Research, 2013, 28, 1007-1013.	3.1	27
75	The Inflammatory Bowel Disease Symptom Inventory: A Patient-report Scale for Research and Clinical Application. Inflammatory Bowel Diseases, 2019, 25, 1277-1290.	0.9	27
76	Modified Delphi Process for the Development of Choosing Wisely for Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2017, 23, 858-865.	0.9	25
77	Understanding Work Experiences of People with Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2016, 22, 1688-1697.	0.9	24
78	Association Between IBD Disability and Reduced Work Productivity (Presenteeism): A Population-Based Study in Manitoba, Canada. Inflammatory Bowel Diseases, 2019, 25, 352-359.	0.9	24
79	Longitudinal Change in Bone Mineral Density in a Population-Based Cohort of Patients with Inflammatory Bowel Disease. Calcified Tissue International, 2012, 91, 356-363.	1.5	23
80	Validating a Measure of Patient Self-efficacy in Disease Self-management Using a Population-based IBD Cohort. Inflammatory Bowel Diseases, 2016, 22, 2165-2172.	0.9	23
81	Upfront Combination Therapy, Compared With Monotherapy, for Patients Not Previously Treated With a Biologic Agent Associates With Reduced Risk of Inflammatory Bowel Disease-related Complications in a Population-based Cohort Study. Clinical Gastroenterology and Hepatology, 2019, 17, 1788-1798.e2.	2.4	23
82	Independent Validation of a Self-Report Version of the IBD Disability Index (IBDDI) in a Population-Based Cohort of IBD Patients. Inflammatory Bowel Diseases, 2018, 24, 766-774.	0.9	22
83	Inflammatory Bowel Disease Increases the Risk of Venous Thromboembolism in Children: A Population-Based Matched Cohort Study. Journal of Crohn's and Colitis, 2021, 15, 2031-2040.	0.6	20
84	The relationship among proton pump inhibitors, bone disease and fracture. Expert Opinion on Drug Safety, 2011, 10, 901-912.	1.0	18
85	Assessing the Relationship between Sources of Stress and Symptom Changes among Persons with IBD over Time: A Prospective Study. Canadian Journal of Gastroenterology and Hepatology, 2016, 2016, 1-8.	0.8	18
86	Herpes Zoster Infection and Herpes Zoster Vaccination in a Population-Based Sample of Persons With IBD: Is There Still an Unmet Need?. Inflammatory Bowel Diseases, 2019, 25, 532-540.	0.9	18
87	Anxiety and Depression Leads to Anti–Tumor Necrosis Factor Discontinuation in Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology, 2021, 19, 1200-1208.e1.	2.4	18
88	Intravenous Versus High-Dose Oral Proton Pump Inhibitor Therapy After Endoscopic Hemostasis of High-Risk Lesions in Patients with Acute Nonvariceal Upper Gastrointestinal Bleeding. Digestive Diseases and Sciences, 2007, 52, 1685-1690.	1.1	16
89	Underutilization of gastroprotective strategies in aspirin users at increased risk of upper gastrointestinal complications. Alimentary Pharmacology and Therapeutics, 2008, 28, 88-96.	1.9	16
90	Health Care Use by a Population-Based Cohort of Children With Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology, 2015, 13, 1302-1309.e3.	2.4	16

#	Article	IF	Citations
91	Cannabis Use in Persons With Inflammatory Bowel Disease and Vulnerability to Substance Misuse. Inflammatory Bowel Diseases, 2020, 26, 1401-1406.	0.9	16
92	Gastroprotective strategies among NSAID users: guidelines for appropriate use in chronic illness. Canadian Family Physician, 2006, 52, 1100-5.	0.1	16
93	Association Between Spring Season of Birth and Crohn's Disease. Clinical Gastroenterology and Hepatology, 2014, 12, 277-282.	2.4	15
94	Health Care Services in IBD. Inflammatory Bowel Diseases, 2017, 23, 1461-1469.	0.9	15
95	Management of Acute Nonvariceal Upper Gastrointestinal Hemorrhage: Comparison of an American and a Canadian Medical Centre. Canadian Journal of Gastroenterology & Hepatology, 2003, 17, 489-495.	1.8	14
96	Patterns and Predictors of Long-term Nonuse of Medical Therapy Among Persons with Inflammatory Bowel Diseases, 2015, 21, 1615-1622.	0.9	13
97	Trends and Predictors of Clostridium difficile Infection among Children: A Canadian Population-Based Study. Journal of Pediatrics, 2019, 206, 20-25.	0.9	13
98	Association Between Change in Inflammatory Aspects of Diet and Change in IBD-related Inflammation and Symptoms Over 1 Year: The Manitoba Living With IBD Study. Inflammatory Bowel Diseases, 2021, 27, 190-202.	0.9	13
99	Earlier Anti-TNF Initiation Leads to Long-term Lower Health Care Utilization in Crohn's Disease but Not in Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 2022, 20, 2607-2618.e14.	2.4	13
100	The prevalence of risk factors for gastrointestinal complications and use of gastroprotection among persons hospitalized for cardiovascular disease. Alimentary Pharmacology and Therapeutics, 2006, 23, 743-749.	1.9	12
101	Physicians' approaches to the use of gastroprotective strategies in low-risk non-steroidal anti-inflammatory drug users. Alimentary Pharmacology and Therapeutics, 2006, 23, 1365-1372.	1.9	12
102	An Assessment of Endoscopic and Concomitant Management of Acute Variceal Bleeding at a Tertiary Care Centre. Canadian Journal of Gastroenterology & Hepatology, 2007, 21, 85-90.	1.8	12
103	Extreme restriction design as a method for reducing confounding by indication in pharmacoepidemiologic research. Pharmacoepidemiology and Drug Safety, 2020, 29, 26-34.	0.9	12
104	Utility of the MARS-5 in Assessing Medication Adherence in IBD. Inflammatory Bowel Diseases, 2021, 27, 317-324.	0.9	12
105	Trends in Corticosteroid Use During the Era of Biologic Therapy: A Population-Based Analysis. American Journal of Gastroenterology, 2021, 116, 1284-1293.	0.2	12
106	Rates and Reasons for Nonuse of Prescription Medication for Inflammatory Bowel Disease in a Referral Clinic. Inflammatory Bowel Diseases, 2016, 22, 919-924.	0.9	11
107	Workplace Accommodation for Persons With IBD: What Is Needed and What Is Accessed. Clinical Gastroenterology and Hepatology, 2017, 15, 1589-1595.e4.	2.4	11
108	Maternal Infections That Would Warrant Antibiotic Use Antepartum or Peripartum Are Not a Risk Factor for the Development of IBD. Inflammatory Bowel Diseases, 2017, 23, 635-640.	0.9	11

#	Article	IF	Citations
109	Effectiveness of Dose De-escalation of Biologic Therapy in Inflammatory Bowel Disease: A Systematic Review. American Journal of Gastroenterology, 2020, 115, 1768-1774.	0.2	11
110	Living With Inflammatory Bowel Disease: Protocol for a Longitudinal Study of Factors Associated With Symptom Exacerbations. JMIR Research Protocols, 2018, 7, e11317.	0.5	11
111	Clinical Practice Guideline for the Medical Management of Perianal Fistulizing Crohn's Disease: The Toronto Consensus. Journal of the Canadian Association of Gastroenterology, 2018, 1, 141-154.	0.1	10
112	Trends of Utilization of Tumor Necrosis Factor Antagonists in Children With Inflammatory Bowel Disease: A Canadian Population-Based Study. Inflammatory Bowel Diseases, 2020, 26, 134-138.	0.9	10
113	A populationâ€based analysis of antidiabetic medications in four Canadian provinces: Secular trends and prescribing patterns. Pharmacoepidemiology and Drug Safety, 2020, 29, 86-92.	0.9	10
114	Cost-effectiveness analysis of a fecal microbiota transplant center for treating recurrent C.difficile infection. Journal of Infection, 2020, 81, 758-765.	1.7	9
115	Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Mental Health and Quality of Life. Journal of the Canadian Association of Gastroenterology, 2021, 4, S46-S53.	0.1	9
116	Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: COVID-19 Vaccines—Biology, Current Evidence and Recommendations. Journal of the Canadian Association of Gastroenterology, 2021, 4, S54-S60.	0.1	9
117	Estimates of Disease Course in Inflammatory Bowel Disease Using Administrative Data: A Population-level Study. Journal of Crohn's and Colitis, 2016, 11, jjw201.	0.6	8
118	Health Care Indicators of Moderate to Severe IBD and Subsequent IBD-Related Disability: A Longitudinal Study. Inflammatory Bowel Diseases, 2019, 25, 1996-2005.	0.9	8
119	Hospital discharge abstracts have limited accuracy in identifying occurrence of Clostridium difficile infections among hospitalized individuals with inflammatory bowel disease: A population-based study. PLoS ONE, 2017, 12, e0171266.	1.1	8
120	Is the attenuated humoral response to COVID-19 vaccination in anti-TNF users relevant?. The Lancet Gastroenterology and Hepatology, 2022, 7, 280-282.	3.7	8
121	Ustekinumab for the treatment of Crohn's disease. Expert Review of Gastroenterology and Hepatology, 2016, 10, 989-994.	1.4	7
122	Coping with Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2017, 23, 1247-1256.	0.9	7
123	Persistence With Immunomodulator Monotherapy Use And Incidence of Therapeutic Ineffectiveness Among Users of Immunomodulator Monotherapy in IBD. American Journal of Gastroenterology, 2018, 113, 1206-1216.	0.2	7
124	Appropriateness of Biologics in the Management of Crohn's Disease Using RAND/UCLA Appropriateness Methodology. Inflammatory Bowel Diseases, 2019, 25, 328-335.	0.9	7
125	Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Health Care Delivery During the Pandemic and the Future Model of Inflammatory Bowel Disease Care. Journal of the Canadian Association of Gastroenterology, 2021, 4, S61-S67.	0.1	7
126	Continued 5ASA use after initiation of antiâ€₹NF or immunomodulator confers no benefit in IBD: a populationâ€based study. Alimentary Pharmacology and Therapeutics, 2021, 54, 814-832.	1.9	7

#	Article	IF	CITATIONS
127	1124 There Is No Decrease in the Mortality From IBD Associated Colorectal Cancers Over 25 Years: A Population Based Analysis. Gastroenterology, 2016, 150, S226-S227.	0.6	6
128	Direct cost of health care for individuals with community associated Clostridium difficile infections: A population-based cohort study. PLoS ONE, 2019, 14, e0224609.	1.1	6
129	A1 LONGITUDINAL CHANGES IN THE DIRECT COST OF IBD CARE IN THE BIOLOGIC ERA. Journal of the Canadian Association of Gastroenterology, 2019, 2, 1-3.	0.1	6
130	Colonoscopic Screening for Colorectal Cancer. JAMA - Journal of the American Medical Association, 2006, 296, 2438.	3.8	5
131	Comparing Resource Utilization and Gastrointestinal Outcomes in Patients Treated with Either Standard-Dose or High-Dose Proton Pump Inhibitors: A Matched Cohort Study. Digestive Diseases and Sciences, 2008, 53, 1519-1526.	1.1	5
132	Editorial: Nonâ€breaking news! Highâ€dose <scp>PPI</scp> s likely do not cause fractures. Alimentary Pharmacology and Therapeutics, 2018, 47, 137-137.	1.9	5
133	IMAGINE Network's Mind And Gut Interactions Cohort (MAGIC) Study: a protocol for a prospective observational multicentre cohort study in inflammatory bowel disease and irritable bowel syndrome. BMJ Open, 2020, 10, e041733.	0.8	5
134	OUP accepted manuscript. Journal of the Canadian Association of Gastroenterology, 2021, 4, S1-S9.	0.1	5
135	What Is a Flare? The Manitoba Living With IBD Study. Inflammatory Bowel Diseases, 2022, 28, 862-869.	0.9	5
136	Cost-Effectiveness of Tight Control for Crohn's Disease With Adalimumab-Based Treatment: Economic Evaluation of the CALM Trial From a Canadian Perspective. Journal of the Canadian Association of Gastroenterology, 2022, 5, 169-176.	0.1	5
137	Selfâ€reported flares among people living with inflammatory bowel disease are associated with stress and worry but not associated with recent diet changes: The Manitoba Living with IBD Study. Journal of Parenteral and Enteral Nutrition, 2022, 46, 1686-1698.	1.3	5
138	Prescribing proton pump inhibitors with clopidogrel. BMJ, The, 2012, 345, e4558-e4558.	3.0	4
139	The Importance of Accounting for Immortal Time Bias in Pharmacoepidemiologic Analyses. American Journal of Gastroenterology, 2015, 110, 349.	0.2	4
140	Emerging issues in the medical management of Crohn $\hat{E}^{1}\!\!/\!\!4$ s disease. Current Opinion in Gastroenterology, 2016, 32, 103-109.	1.0	4
141	Independent Validation of a Self-Report Version of the IBD Disability Index (IBDDI) in a Population-Based Cohort of IBD Patients. Gastroenterology, 2017, 152, S25.	0.6	4
142	Concomitant Immunomodulator is Associated with a Decreased Risk of Anti-TNF Discontinuation and Substitution: A Population Based Study. Gastroenterology, 2017, 152, S970.	0.6	4
143	Editorial: let's take a break from studying the ⟨scp⟩PPI⟨/scp⟩â€fracture association. Alimentary Pharmacology and Therapeutics, 2018, 47, 1543-1544.	1.9	4
144	A Population-Based Study of Combination vs Monotherapy of Anti-TNF in Persons With IBD. Inflammatory Bowel Diseases, 2020, 26, 150-157.	0.9	4

#	Article	IF	CITATIONS
145	Management of Biological Therapy Before Elective Inflammatory Bowel Disease Surgeries. Inflammatory Bowel Diseases, 2019, 25, 1613-1620.	0.9	4
146	Providing Hospitalized Ulcerative Colitis Patients With Practice Guidelines Improves Patient-Reported Outcomes. Journal of the Canadian Association of Gastroenterology, 2020, 4, 131-136.	0.1	4
147	OUP accepted manuscript. Journal of the Canadian Association of Gastroenterology, 2021, 4, S40-S45.	0.1	4
148	The complex relationship between diet, symptoms, and intestinal inflammation in persons with inflammatory bowel disease: The Manitoba Living With IBD Study. Journal of Parenteral and Enteral Nutrition, 2021, , .	1.3	4
149	The association of efficacy, optimism, uncertainty and health anxiety with inflammatory bowel disease activity. Journal of Psychosomatic Research, 2022, 154, 110719.	1.2	4
150	Another bad break for proton-pump inhibitors?. Nature Reviews Rheumatology, 2009, 5, 478-480.	3.5	3
151	Immortal time bias and infliximab-related mortality and malignancy incidence. Gut, 2010, 59, 416-416.	6.1	3
152	223 Patterns of Drug Avoidance in Patients With Inflammatory Bowel Disease. Gastroenterology, 2013, 144, S-48-S-49.	0.6	3
153	What is the role for bisphosphonates in IBD?. Gut, 2014, 63, 1369-1370.	6.1	3
154	164 Dietary Lactose Consumption Is Associated With Both Increased Symptoms and Intestinal Inflammation in IBD. Gastroenterology, 2016, 150, S41-S42.	0.6	3
155	Mo1871 - Direct Costs of Care Among Patients with Inflammatory Bowel Disease before and after Initiation of Anti-TNF Therapy. Gastroenterology, 2018, 154, S-833.	0.6	3
156	The Clinician's Guide to Proton-Pump Inhibitor Discontinuation. Journal of Clinical Gastroenterology, 2019, 53, 553-559.	1.1	3
157	The Cost of Use of the Emergency Department by Persons With Inflammatory Bowel Disease Living in a Canadian Health Region: A Retrospective Population-Based Study. Journal of the Canadian Association of Gastroenterology, 2020, 3, 135-140.	0.1	3
158	OUP accepted manuscript. Journal of the Canadian Association of Gastroenterology, 2021, 4, S27-S33.	0.1	3
159	The Risk of Early and Late Colectomy in Patients With Ulcerative Colitis: Results From a Population-Based Cohort. Gastroenterology, 2011, 140, S-113-S-114.	0.6	2
160	Sa1201 Development of an IBD Symptom Self-Report Scale for Research and Clinical Application. Gastroenterology, 2014, 146, S-228-S-229.	0.6	2
161	Are We Worried Enough About Selective Serotonin Receptor Inhibitors and Upper Gastrointestinal Bleeding?. Clinical Gastroenterology and Hepatology, 2015, 13, 51-54.	2.4	2
162	Editorial: understanding sex and gender dimorphism in chronic diseases may improve outcomes. Alimentary Pharmacology and Therapeutics, 2019, 50, 603-604.	1.9	2

#	Article	IF	CITATIONS
163	Gastroenterologist Consultation Is Uncommon but Associated with Improved Care Among IBD Patients Presenting to Emergency Departments in Winnipeg Hospitals. Journal of the Canadian Association of Gastroenterology, 2021, 4, 57-64.	0.1	2
164	Crohn's and Colitis Canada's 2021 Impact of COVID-19 & Disease in Canada: A Knowledge Translation Strategy. Journal of the Canadian Association of Gastroenterology, 2021, 4, S10-S19.	0.1	2
165	Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Seniors With IBD. Journal of the Canadian Association of Gastroenterology, 2021, 4, S34-S39.	0.1	2
166	The Relationship Between Inflammatory Bowel Disease and Bone Mineral Density. Results of a Population-based Study. American Journal of Gastroenterology, 2011, 106, S492.	0.2	2
167	Do persons with acute, non-variceal upper gi hemorrhage (UGIH) require admission to an icuimonitored bed? Comparison of a canadian and us center. Gastroenterology, 2000, 118, A893.	0.6	1
168	The Infusion Illusion. American Journal of Gastroenterology, 2008, 103, 3019-3021.	0.2	1
169	Proton pump inhibitors and osteoporosis-related fractures. Cmaj, 2009, 180, 643-644.	0.9	1
170	Proton pump inhibitors and osteoporosis-related fractures. Cmaj, 2009, 180, 643-643.	0.9	1
171	A Population-Based Study of Prevalence and Predictors of Hospitalization in UC. Gastroenterology, 2011, 140, S-780.	0.6	1
172	Immortal Time Bias: A Likely Alternate Explanation for the Purported Benefits of DXA Screening in Ulcerative Colitis. American Journal of Gastroenterology, 2014, 109, 1689.	0.2	1
173	Su1348 The Non Use of IBD-Specific Prescription Medications in Patients With IBD. Gastroenterology, 2014, 146, S-443.	0.6	1
174	No Increase in Immunomodulator Use in Combination with Anti-TNF Therapy in the Post Sonic ERA. Gastroenterology, 2017, 152, S400.	0.6	1
175	Preferences for Care for Active Symptoms of IBD in a Population Based Sample. Gastroenterology, 2017, 152, S365.	0.6	1
176	Sa1073 - Time Trends of Laboratory Confirmed Clostridium Difficile Infections in an Entire Province Suggest an Increasing Shift to Community Acquired Infections and Younger Age of Acquiring Infections. Gastroenterology, 2018, 154, S-230-S-231.	0.6	1
177	179â€fCost-Effectiveness Analysis of Starting a Fecal Microbiota Transplantation (FMT) Unit for the Treatment of Recurrent C. difficile Infection Compared With Antibiotic Therapy. American Journal of Gastroenterology, 2019, 114, S110-S110.	0.2	1
178	Re-cherchez la Femme: A Second Look at Women in Gastroenterology in Canada. Journal of the Canadian Association of Gastroenterology, 2020, 3, 55-56.	0.1	1
179	Time trends and predictors of laboratory-confirmed recurrent and severe <i>Clostridioides difficile </i> infections in Manitoba: a population-based study. CMAJ Open, 2020, 8, E737-E746.	1.1	1
180	PO43 FOCUSING ON THE FUTURE: REDUCING BARRIERS AND IMPROVING ACCESS TO IBD SPECIALTY CARE ACROSS CANADA. Inflammatory Bowel Diseases, 2020, 26, S63-S63.	0.9	1

#	Article	IF	Citations
181	Su1805 THE LONG-TERM CORTICOSTEROID SPARING EFFECT OF ANTI-TNF THERAPY IN A REAL WORLD CROHN'S DISEASE COHORT. Gastroenterology, 2020, 158, S-655.	0.6	1
182	Proton Pump Inhibitors Are Associated with Decreased Bone Mineral Density. American Journal of Gastroenterology, 2011, 106, S405-S406.	0.2	1
183	Dose Augmentation of Tumor Necrosis Factor Inhibitors is Frequently Performed in Persons With Inflammatory Bowel Disease in the Absence of Objective Evidence of Active Inflammation. Journal of Clinical Gastroenterology, 2020, Publish Ahead of Print, 602-608.	1.1	1
184	Pregnancy and Live Birth Rates Over Time in Women With Inflammatory Bowel Disease: A Population-Based Cohort Study. Journal of the Canadian Association of Gastroenterology, 2022, 5, 184-191.	0.1	1
185	Which low-risk patients with acute, non-variceal upper GI hemorrhage are candidates for early discharge?. Gastroenterology, 2000, 118, A466.	0.6	O
186	Is Endoscopic Ultrasound (EUS) Appropriate for the Diagnosis of Perianal Fistula in Crohn's Disease (CD)? A Survey of North American Inflammatory Bowel Disease (IBD) Experts. Gastrointestinal Endoscopy, 2005, 61, AB275.	0.5	0
187	The Cost Effectiveness of Colonic Stenting As a Bridge to Curative Surgery in Patients with Acute Left-Sided Malignant Colonic Obstruction: A Canadian Perspective. Gastrointestinal Endoscopy, 2006, 63, AB98.	0.5	0
188	Colorectal Cancer Risk Following a Negative Colonoscopyâ€"Reply. JAMA - Journal of the American Medical Association, 2006, 296, 2436.	3.8	0
189	Preâ€endoscopic PPI therapy reduces recurrent adverse outcomes in acute nonâ€variceal upper gastrointestinal bleeding: authors' reply. Alimentary Pharmacology and Therapeutics, 2007, 25, 344-345.	1.9	0
190	Prescription Drug Use in IBD: A Population Based Study. Gastroenterology, 2011, 140, S-778-S-779.	0.6	0
191	The association between proton pump inhibitor use and hip fracture cannot be explained by differences in dietary and lifestyle choices. Evidence-Based Medicine, 2013, 18, 38-39.	0.6	0
192	Reply. Gastroenterology, 2015, 149, 1634.	0.6	0
193	A Preliminary Study of DXA and QCT Derived Femur Cross-Section Stiffness. Applied Mechanics and Materials, 2015, 775, 415-419.	0.2	O
194	Failure to Account for Immortal Person Time Likely Accounts for the Apparent Reduction in Surgery Among Natalizumab Users. Clinical Gastroenterology and Hepatology, 2016, 14, 776.	2.4	0
195	18 Emergency Department Use by Persons With IBD; A Population Based Study. Gastroenterology, 2016, 150, S6.	0.6	O
196	Mo1797 Maternal Antibiotic Use Antepartum or Peripartum Period Is Not Associated With the Development of IBD in offspring: A Population Based Analysis. Gastroenterology, 2016, 150, S778-S779.	0.6	0
197	Herpes Zoster Infection and Herpes Zoster Vaccination in IBD: A Need for Improvement in Vaccination Rates. Gastroenterology, 2017, 152, S971-S972.	0.6	0
198	What are the Most Common Symptoms Reported in a Self-Reported Flare of IBD? the Manitoba Living with IBD Study. Gastroenterology, 2017, 152, S376-S377.	0.6	0

#	Article	IF	CITATIONS
199	The Prevalence and Predictors of Anti-TNF Failure in a Population based Sample of Persons with IBD. Gastroenterology, 2017, 152, S360-S361.	0.6	0
200	A Survey of Workplace Accommodations among Persons with IBD. Gastroenterology, 2017, 152, S123-S124.	0.6	0
201	A Survey of Patient Views of Factors Producing Symptom Exacerbations in the Living with IBD Study. Gastroenterology, 2017, 152, S365.	0.6	O
202	What is a Flare of IBD?: The Manitoba Living with IBD Study. Gastroenterology, 2017, 152, S27.	0.6	0
203	Association between IBD Disability and Reduced Work Productivity (Presenteeism): A Population-Based Study in Manitoba, Canada. Gastroenterology, 2017, 152, S375.	0.6	O
204	Evaluation of Knowledge Translation Resources for Patients about IBD and its Management. Gastroenterology, 2017, 152, S799-S800.	0.6	0
205	Studies Using Hospital Discharge Databases may Underestimate Occurrence of Clostridium Difficile Infections Among Hospitalized Individuals with Inflammatory Bowel Disease. Gastroenterology, 2017, 152, S979.	0.6	O
206	The Economics of Inflammatory Bowel Disease. Clinical Gastroenterology, 2017, , 345-355.	0.0	0
207	Reply. Gastroenterology, 2018, 154, 256-257.	0.6	O
208	A34 TRENDS AND PREDICTORS OF CLOSTRIDIUM DIFFICILE INFECTION AMONG THE CHILDREN OF MANITOBA: A POPULATION-BASED STUDY. Journal of the Canadian Association of Gastroenterology, 2018, 1, 57-58.	0.1	0
209	A105 CANADIAN WOMEN WITH IBD ARE MORE LIKELY TO GIVE BIRTH TO LOW BIRTH WEIGHT INFANTS. Journal of the Canadian Association of Gastroenterology, 2018, 1, 159-160.	0.1	O
210	Reply to Letter to Editor of Dr. Elia. Inflammatory Bowel Diseases, 2019, 25, e9-e9.	0.9	0
211	What Constitutes Frailty In Inflammatory Bowel Disease?. Gastroenterology, 2020, 159, 1993.	0.6	O
212	OUP accepted manuscript. Journal of the Canadian Association of Gastroenterology, 2021, 4, S20-S26.	0.1	0
213	A172 THE ASSOCIATION OF EFFICACY, OPTIMISM, UNCERTAINTY AND HEALTH ANXIETY IN INFLAMMATORY BOWEL DISEASE ACTIVITY OVER TIME. Journal of the Canadian Association of Gastroenterology, 2021, 4, 183-184.	0.1	O
214	A155 REAL-WORLD USE OF CORTIMENT IN ULCERATIVE COLITIS: A POPULATION-BASED STUDY. Journal of the Canadian Association of Gastroenterology, 2021, 4, 161-162.	0.1	0
215	Editorial: 5â€ASA in IBD patients on biologics—'stop or continue'? Authors' reply. Alimentary Pharmacology and Therapeutics, 2021, 54, 845-845.	1.9	0
216	Is Inflammatory Bowel Disease a Risk Factor for Fracture? An Analysis Using the Fracture Risk Assessment Tool (FRAX): 2011 ACG Presidential Poster. American Journal of Gastroenterology, 2011, 106, S431.	0.2	0

#	Article	IF	CITATIONS
217	Author's reply to Witham and colleagues. BMJ, The, 2012, 345, e5852-e5852.	3.0	O
218	Predictors of Academic Performance among Children with Inflammatory Bowel Disease: A Population-based Study. American Journal of Gastroenterology, 2013, 108, S555.	0.2	0
219	Clostridium difficile Infections Among Hospitalized Individuals With IBD. American Journal of Gastroenterology, 2017, 112, S340-S342.	0.2	O
220	A158 COMPARING CORTIMENT® AND PREDNISONE IN ULCERTATIVE COLITIS: A POPULATION-BASED STUDY OF OUTCOMES. Journal of the Canadian Association of Gastroenterology, 2022, 5, 33-35.	0.1	0